Hamburg, Germany
Breakpoint Therapeutics, founded in 2019, is a German-based biotechnology startup with a compelling focus on cancer treatment innovation. Their slogan, "Modulating DNA damage responses to cure cancer," aptly captures the essence of their core mission.
The company aims to develop first-in-class oncology drugs targeting the DNA damage response (DDR) in cancer cells. These drugs are designed to disrupt DNA repair and replication stress tolerance pathways, providing a promising complement to existing PARP inhibitors. This approach seeks to tackle therapy-resistant cancers, an area with significant unmet medical needs.
In their last investment round on 09 July 2019, Breakpoint Therapeutics raised €30.00M from investors including Evotec, Taiho Ventures, and Medicxi. With their strategic focus and strong investor backing, the company is well-positioned for clinical advancements in the healthcare sector.
